98%
921
2 minutes
20
Objective: Our goal was to reduce the prevalence of antipsychotic medication side-effects by providing a short-term training program on the assessment and management of side-effects to case managers.
Method: Forty-four patients in receipt of community-based mental health services were allocated to comparison (n = 20) and intervention (n = 24) groups based on the health service district in which they resided. While case managers working with the intervention group attended a short-term training program to improve their assessment and management of neuroleptic side-effects, case managers providing services to the comparison group received no additional training. Side-effects were assessed pre- and postintervention using the Liverpool University Neuroleptic Side-effect Rating Scale (LUNSERS).
Results: A reduction in the overall prevalence of side-effects in both groups was observed, however, only those patients in the intervention group reported a statistically significant reduction in mean side-effect scores between the pre- and postmeasures (Wilcoxon Matched Pairs Signed-ranks Test, z = -2.8411, two-tailed, p < 0.01). In addition, qualitative data collected during the second survey revealed that patients in the intervention group had acquired some positive management strategies for dealing with unwanted side-effects. The strategies were elicited from eight different patients distributed across six of the 12 case managers who took part in the training program.
Conclusions: Training cases managers in the assessment and management of side-effects may help to reduce their impact on the lives of people prescribed neuroleptic medication.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/j.1440-1614.2000.00821.x | DOI Listing |
Health Inf Manag
September 2025
Health Information Technology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Background: The success of disease registry systems (DRSs) depends on developing software that aligns with the registry's specific needs.
Objective: This study focuses on localising the Checklist with Items for Patient Registry sOftware Systems (CIPROS) to facilitate the DRS assessment.
Method: This applied and cross-sectional study was carried out in 2023 in six phases.
J Investig Allergol Clin Immunol
September 2025
Department of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Background And Objectives: Pollen-food allergy syndrome (PFAS) is a frequent comorbidity in individuals with hay fever. Identifying risk factors and allergen clusters can aid targeted interventions and management strategies. Objective: This study characterizes PFAS in patients with hay fever and identifies associated risk factors using the mobile health platform, AllerSearch.
View Article and Find Full Text PDFCirculation
September 2025
Division of Cardiology, Columbia University Irving Medical Center, New York, NY (S.A.P.).
Background: Limited treatment options exist for infrapopliteal disease in patients with chronic limb-threatening ischemia (CLTI), a condition associated with a high risk of limb loss. Interventional management of diseased infrapopliteal vessels with percutaneous transluminal angioplasty (PTA) is associated with high rates of restenosis and reintervention. In the LIFE-BTK trial, the drug-eluting resorbable scaffold (DRS) demonstrated superior 12-month efficacy compared with PTA in a selected CLTI population with predominantly noncomplex, mildly to moderately calcified lesions.
View Article and Find Full Text PDFStroke
September 2025
Department of Rehabilitation Medicine, West China Hospital, Sichuan University, Chengdu, China (H.Z., K.H., Q.G.).
Background: Poststroke cognitive impairment (PSCI) affects 30% to 50% of stroke survivors, severely impacting functional outcomes and quality of life. This study uses functional near-infrared spectroscopy (fNIRS) to assess task-evoked brain activation and its potential for stratifying the severity in patients with PSCI.
Method: A cross-sectional study was conducted at Nanchong Central Hospital between June 2023 and April 2024.